Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash from Financing Activities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash from Financing Activities for 16 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.3 million through Dec 2025, up 389.91% year-over-year, with the annual reading at $30.3 million for FY2025, 389.91% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.8 million at Plus Therapeutics, down from $12.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $12.4 million in Q1 2025, with the low at -$776000.0 in Q1 2024.
  • Average Cash from Financing Activities over 5 years is $4.2 million, with a median of $2.8 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities skyrocketed 51161.11% in 2021, then plummeted 634.34% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $9.2 million in 2021, then tumbled by 98.92% to $99000.0 in 2022, then tumbled by 634.34% to -$529000.0 in 2023, then skyrocketed by 1416.26% to $7.0 million in 2024, then plummeted by 59.74% to $2.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.8 million, $12.3 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.